

 



<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
  "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"
      xmlns:foaf="http://xmlns.com/foaf/0.1/"
      xmlns:dc="http://purl.org/dc/terms/"
      xmlns:doi="http://dx.doi.org/"
      xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
      xmlns:xsd="http://www.w3.org/2001/XMLSchema-datatypes#"
      lang="en" xml:lang="en"
      itemscope itemtype="http://schema.org/Article"
      class="no-js">
<head prefix="og: http://ogp.me/ns#">
  <title>PLOS ONE: Investigation of False Positive Results with an Oral Fluid Rapid HIV-1/2 Antibody Test</title>


<link rel="stylesheet" type="text/css"  href="/css/global-min.css?v=izteQ6tu7kgsJZW_xmrYizvKiHM" />


    <!--[if lte IE 7]>
<link rel="stylesheet" type="text/css"  href="/css/lte_ie7-min.css?v=3bykQUyQmReeuobVyPozcJ9LxRc" />
    <![endif]-->


<link rel="stylesheet" type="text/css"  href="/css/jquery-ui-min.css?v=eXDHTEJM0lIAmDe5k0I0Ad4nxNo" />


<link rel="stylesheet" type="text/css"  href="/css/journal.css?v=T7ZVxJfgk9jNxLAJ2qHz1vZpgYU" />


<link rel="stylesheet" type="text/css" media="print" href="/css/print-min.css?v=T5lb0B3q6EXBsuDluc5V5w+AkRc" />


  <link rel="stylesheet" href="http://f.fontdeck.com/s/css/js/www.plosone.org/24557.css" type="text/css"/>

  <!--chartbeat -->
  <script type="text/javascript">var _sf_startpt = (new Date()).getTime()</script>
  <script>document.documentElement.className += ' js';</script>

  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <meta http-equiv="X-UA-Compatible" content="IE=EmulateIE7; IE=EmulateIE9"/>
  <meta name="description" content="PLOS ONE: an inclusive, peer-reviewed, open-access resource from the PUBLIC LIBRARY OF SCIENCE. Reports of well-performed scientific studies from all disciplines freely available to the whole world."/>
  <meta name="keywords" content="PLOS, Public Library of Science, Open Access, Open-Access, Science, Medicine, Biology, Research, Peer-review, Inclusive, Interdisciplinary, Ante-disciplinary, Physics, Chemistry, Engineering"/>
  <meta name="almHost" content="http://alm.plos.org/api/v3/articles"/>
  <meta name="searchHost" content="http://api.plos.org/search" />
  <meta name="termsHost" content="http://api.plos.org/terms" />
  <meta name="solrApiKey" content="plos"/>
  <meta name="almAPIKey" content="3pezRBRXdyzYW6ztfwft" />
  <meta name="currentJournal" content="PLoSONE" />
  <meta name="almRequestBatchSize" content="" />

  <meta name="citation_publisher" content="Public Library of Science"/>
  <meta name="citation_doi" content="10.1371/journal.pone.0000185"/>
  <meta name="dc.identifier" content="10.1371/journal.pone.0000185" />

    <meta name="citation_title" content="Investigation of False Positive Results with an Oral Fluid Rapid HIV-1/2 Antibody Test"/>
    <meta itemprop="name" content="Investigation of False Positive Results with an Oral Fluid Rapid HIV-1/2 Antibody Test"/>

      <meta name="citation_author" content="Krishna Jafa"/>
            <meta name="citation_author_institution" content="Division of HIV/AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America"/>
            <meta name="citation_author_institution" content="Epidemiology Program Office, Office of Workforce and Career Development, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America"/>
      <meta name="citation_author" content="Pragna Patel"/>
            <meta name="citation_author_institution" content="Division of HIV/AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America"/>
      <meta name="citation_author" content="Duncan A. MacKellar"/>
            <meta name="citation_author_institution" content="Division of HIV/AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America"/>
      <meta name="citation_author" content="Patrick S. Sullivan"/>
            <meta name="citation_author_institution" content="Division of HIV/AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America"/>
      <meta name="citation_author" content="Kevin P. Delaney"/>
            <meta name="citation_author_institution" content="Division of HIV/AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America"/>
      <meta name="citation_author" content="Tracy L. Sides"/>
            <meta name="citation_author_institution" content="Infectious Disease Epidemiology, Prevention and Control Division, Minnesota Department of Health, Saint Paul, Minnesota, United States of America"/>
      <meta name="citation_author" content="Alexandra P. Newman"/>
            <meta name="citation_author_institution" content="Wisconsin Division of Public Health, Madison, Wisconsin, United States of America"/>
            <meta name="citation_author_institution" content="Epidemiology Program Office, Office of Workforce and Career Development, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America"/>
      <meta name="citation_author" content="Sindy M. Paul"/>
            <meta name="citation_author_institution" content="New Jersey Department of Health and Senior Services, Division of HIV/AIDS Services, Trenton, New Jersey, United States of America"/>
      <meta name="citation_author" content="Evan M. Cadoff"/>
            <meta name="citation_author_institution" content="Department of Pathology and Laboratory Medicine, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, United States of America"/>
      <meta name="citation_author" content="Eugene G. Martin"/>
            <meta name="citation_author_institution" content="Department of Pathology and Laboratory Medicine, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, United States of America"/>
      <meta name="citation_author" content="Patrick A. Keenan"/>
            <meta name="citation_author_institution" content="Department of Family Medicine and Community Health, University of Minnesota School of Medicine, Minneapolis, Minnesota, United States of America"/>
      <meta name="citation_author" content="Bernard M. Branson"/>
            <meta name="citation_author_institution" content="Division of HIV/AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America"/>
      <meta name="citation_author" content="for the OraQuick Study Group"/>

    <meta name="citation_date" content="2007/1/31"/>

  <meta name="citation_pdf_url" content="http://dx.plos.org/10.1371/journal.pone.0000185.pdf" />

      <meta name="citation_journal_title" content="PLOS ONE" />
    <meta name="citation_firstpage" content="e185"/>
    <meta name="citation_issue" content="1"/>
    <meta name="citation_volume" content="2"/>
    <meta name="citation_issn" content="1932-6203"/>

    <meta name="citation_journal_abbrev" content="PLoS ONE" />

      <meta name="citation_reference" content="citation_title=OraQuick Advance rapid HIV-1/2 antibody test [package insert]. Bethlehem, Pennsylvania: Orasure Technologies.; citation_number=1; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=CLIA certificate of waiver fact sheet.; citation_number=2; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Advancing HIV Prevention: new strategies for a changing epidemic—United States, 2003.; citation_volume=52; citation_number=3; citation_pages=329-332; citation_date=2003; " />
      <meta name="citation_reference" content="citation_title=Performance of an oral fluid rapid HIV 1/2 test: experience from four CDC studies.; citation_author=KP Delaney; citation_author=A Uniyal; citation_author=PR Kerndt; citation_author=A Gardener; citation_author=PA Keenan; citation_volume=20; citation_number=4; citation_pages=1655-1660; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Development of rapid HIV tests. Presented at: Blood Products Advisory Committee Sixty-Sixth Meeting; Volume I; Silver Spring, Maryland.; citation_number=5; citation_date=2000; " />
      <meta name="citation_reference" content="citation_title=The use of confidence or fiducial limits illustrated in the case of the binomial.; citation_author=C Clopper; citation_author=E Pearson; citation_journal_title=Biometrika; citation_volume=26; citation_number=6; citation_pages=404-413; citation_date=1934; " />
      <meta name="citation_reference" content="citation_title=Post marketing surveillance of OraQuick® whole blood and oral fluid rapid HIV testing.; citation_author=LG Wesolowski; citation_author=DA MacKellar; citation_author=SN Facente; citation_author=T Dowling; citation_author=SF Ethridge; citation_volume=20; citation_number=7; citation_pages=1661-1666; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=HIV counseling with rapid tests.; citation_number=8; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Notice to readers: Protocols for confirmation of reactive rapid HIV tests.; citation_volume=53; citation_number=9; citation_pages=221-2; citation_date=2004; " />

  <link rel="canonical" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0000185" />

    <meta name="twitter:card" content="summary"/>
    <meta name="twitter:site" content="@plosone"/>
    <meta name="twitter:title" content="Investigation of False Positive Results with an Oral Fluid Rapid HIV-1/2 Antibody Test"/>
    <meta name="twitter:description" content="BackgroundIn March 2004, the OraQuick&reg; rapid HIV antibody test became the first rapid HIV test approved by the US Food and Drug Administration for use on oral fluid specimens. Test results are available in 20 minutes, and the oral fluid test is non-invasive. From August 2004&ndash;June 2005, we investigated a sudden increase in false-positive results occurring in a performance study of OraQuick&reg; oral-fluid rapid HIV tests in Minnesota.Methodology/Principal FindingsIn a field investigation, we reviewed performance study data on oral-fluid and whole-blood OraQuick&reg; rapid HIV test device lots and expiration dates and assessed test performance and interpretation with oral-fluid and whole-blood specimens by operators who reported false-positive results. We used multivariate logistic regression to evaluate client demographic and risk characteristics associated with false-positive results. Next, we conducted an incidence study of false-positive OraQuick rapid HIV tests in nine US cities and tested both oral-fluid and finger-stick whole-blood specimens from clients; reactive tests were confirmed with Western blot. Sixteen (4.1%) false-positive oral-fluid results occurred in the performance study from April 15, 2004 through August 31, 2004 with unexpired devices from six test lots among 388 HIV-uninfected clients (specificity, 95.9%; 95% CI: 93.4&ndash;97.6). Three test operators who had reported false-positive results performed and interpreted the test according to package-insert instructions. In multivariate analysis, only older age was significantly associated with false-positive results (adjusted odds ratio&#8202;=&#8202;4.5, 95% CI: 1.2&ndash;25.7). In the incidence study, all valid oral-fluid and whole-blood results from 2,268 clients were concordant and no false-positive results occurred (100% specificity).Conclusions/SignificanceThe field investigation did not identify a cause for the increase in false-positive oral-fluid results, and the incidence study detected no false-positive results. The findings suggest this was an isolated cluster; the test's overall performance was as specified by the manufacturer."/>
      <meta name="twitter:image" content="http://dx.plos.org/10.1371/journal.pone.0000185.g001"/>

  <meta property="og:title" content="Investigation of False Positive Results with an Oral Fluid Rapid HIV-1/2 Antibody Test" />
  <meta property="og:type" content="article" />
  <meta property="og:url" content="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0000185" />

 <!--end articleInfoX-->

  <link rel="pingback" href="http://www.plosone.org/pingback" />


  <link rel="shortcut icon" href="/images/favicon.ico" type="image/x-icon"/>
  <link rel="home" title="home" href="/"/>
  <link rel="alternate" type="application/rss+xml"
        title="PLOS ONE: New Articles"
        href="http://www.plosone.org/article/feed"/>
</head>
<body>

  <div id="page-wrap">
    <div id="topbanner" class="cf">

<!-- Div for the ad at the top of journal home page-->
<div class="center">
  <div class="title">Advertisement</div>
  <iframe id='a3ac9da4' name='a3ac9da4'
    src='http://ads.plos.org/www/delivery/afr.php?zoneid=345&amp;cb=8783'
    frameborder='0' scrolling='no' width='730' height='90'>
    <a href='http://ads.plos.org/www/delivery/ck.php?n=a3ac9da4&amp;cb=5651'
      target='_top'><img src='http://ads.plos.org/www/delivery/avw.php?zoneid=345&amp;cb=676&amp;n=a3ac9da4'
      border='0' alt=''/>
    </a>
  </iframe>
</div>    </div>

    <div id="pagehdr-wrap">
      <div id="pagehdr">
        <div id="user" class="nav">
          <ul>
            <li><a href="http://www.plos.org">plos.org</a></li>
            <li><a href="https://register.plos.org/ambra-registration/register.action">create account</a></li>
            <li class="btn-style"><a
              href="/user/secure/secureRedirect.action?goTo=%2Farticle%2FfetchArticle.action%3FarticleURI%3Dinfo%253Adoi%252F10.1371%252Fjournal.pone.0000185">sign in</a>
            </li>
          </ul>
        </div>
        <div class="logo">
          <a href="/"><img src="/images/logo.png" alt="PLOS ONE"></a>
        </div>

<div id="nav-main" class="nav">
  <ul>
        <li id="mn-01"><a href="/taxonomy" class="areas-link">Subject Areas</a></li>
    <li id="mn-02"><a href="javascript:void(0);">For Authors</a>
      <div class="submenu" style="width: 540px; margin-left: -300px;">
        <div class="block">
          <div class="submit-script">
            <h3>Submit your Manuscript</h3>
            <ul>
              <li>Fair, rigorous peer review</li>
              <li>Broad scope and wide reach</li>
            </ul>
            <a href="/static/submissionInstructions" class="btn">get started</a>
          </div>
        </div>
        <div class="menu">
          <ul>
            <li><a href="/static/publish">Why Publish with PLOS ONE</a></li>
            <li><a href="/static/publication">Publication Criteria</a></li>
            <li><a href="/static/editorial">Editorial Policies</a></li>
            <li><a href="/static/guidelines">Preparing A Manuscript</a></li>
            <li><a href="/static/figureGuidelines">Figure and Table Guidelines</a></li>
          <li><a href="/static/supportingInformation">Supporting Information Guidelines</a></li>
            <li><a href="/static/submissionInstructions">Submitting a Manuscript</a></li>
          </ul>
        </div>
      </div>
    </li>

    <li id="mn-03"><a href="javascript:void(0);">About Us</a>
      <div class="submenu" style="width:248px; margin-left:-30px;">
        <div class="menu">
          <ul>
            <li><a href="/static/information">Journal Information</a></li>
            <li><a href="/static/edboard">Editorial Board</a></li>
            <li><a href="/static/reviewerGuidelines">Reviewer Guidelines</a></li>
            <li><a href="/static/almInfo">Article-Level Metrics</a></li>
            <li><a href="/static/license">Open-Access License</a></li>
            <li><a href="/static/downloads">Media Downloads</a></li>
            <li><a href="/static/commentGuidelines">Guidelines for Comments</a></li>
            <li><a href="/static/corrections">Corrections</a></li>
            <li><a href="/static/help">Help Using this Site</a></li>
            <li><a href="/static/contact">Contact Us</a></li>
          </ul>
        </div>
      </div>
    </li>
  </ul>
<div id="db">
  <form name="searchForm" action="/search/simple?noSearchFlag=true&amp;query=&amp;articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0000185" method="get" >
<input type="hidden" name="from" value="globalSimpleSearch" id="from"/><input type="hidden" name="filterJournals" value="PLoSONE" id="filterJournals"/>    <fieldset>
      <legend>Search</legend>
      <label for="search">Search</label>
      <div class="wrap">
        <input id="search" type="text" name="query" placeholder="Search">
        <input type="image" alt="SEARCH" src="/images/icon.search.gif">
      </div>
    </fieldset>
  </form>
    <a id="advSearch" href="/search/advanced?noSearchFlag=true&amp;query=&amp;articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0000185&filterJournals=PLoSONE">advanced search</a>
</div></div>

      </div>
      <!-- pagehdr-->
    </div>
    <!-- pagehdr-wrap -->

  <!--body and html tags gets closed in global_footer.ftl-->
<script type="text/javascript" src="/javascript/mathjax/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>

<div id="pagebdy-wrap">
  <div id="pagebdy">

    <div id="article-block" class="cf">

<div class="article-meta cf">
  <ul id="almSignPost" style="display: none;"></ul>
  <div class="article-type">
    <span class="type oa">Open Access</span>
      <span class="type pr">Peer-Reviewed</span>
  </div>
</div>

<div class="header" id="hdr-article">

<div class="article-kicker">
      <span id="article-type-heading">
        Research Article
      </span>
</div>  <h1 property="dc:title" datatype="" rel="dc:type" href="http://purl.org/dc/dcmitype/Text">
    Investigation of False Positive Results with an Oral Fluid Rapid HIV-1/2 Antibody Test
  </h1>

  <ul class="authors">
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Krishna Jafa
              <span class="corresponding">mail</span>, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              <p><span class="email">*</span>To whom correspondence should be addressed. E-mail: <a href="mailto:kjafa@cdc.gov">kjafa@cdc.gov</a>
            </p>

                <p>Affiliations:
                  Division of HIV/AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 
                  Epidemiology Program Office, Office of Workforce and Career Development, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Pragna Patel, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Division of HIV/AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Duncan A. MacKellar, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Division of HIV/AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Patrick S. Sullivan, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Division of HIV/AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Kevin P. Delaney, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Division of HIV/AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Tracy L. Sides, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Infectious Disease Epidemiology, Prevention and Control Division, Minnesota Department of Health, Saint Paul, Minnesota, United States of America
                </p>

                <p>
                    Current address: Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, Minnesota, United States of America
                </p>

              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Alexandra P. Newman, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliations:
                  Wisconsin Division of Public Health, Madison, Wisconsin, United States of America, 
                  Epidemiology Program Office, Office of Workforce and Career Development, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Sindy M. Paul, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  New Jersey Department of Health and Senior Services, Division of HIV/AIDS Services, Trenton, New Jersey, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Evan M. Cadoff, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Department of Pathology and Laboratory Medicine, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Eugene G. Martin, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Department of Pathology and Laboratory Medicine, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Patrick A. Keenan, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Department of Family Medicine and Community Health, University of Minnesota School of Medicine, Minneapolis, Minnesota, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Bernard M. Branson, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Division of HIV/AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author no_author_meta">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            for the OraQuick Study Group
          </span>
        </span>

      </li>
  </ul>
  <ul class="date-doi-line">
    <li>Published: January 31, 2007</li>
    <li>DOI: 10.1371/journal.pone.0000185</li>
  </ul>


</div><!--end header-->
<div class="main cf" id="pjax-container">
  

<div class="nav items-5" id="nav-article">
  <ul>
  <li>
        <span class="active" name="article">Article</span>
  </li>
  <li>
      <a href="/article/authors/info%3Adoi%2F10.1371%2Fjournal.pone.0000185" name="authors">About the Authors</a>
  </li>
  <li>
      <a href="/article/metrics/info%3Adoi%2F10.1371%2Fjournal.pone.0000185" name="metrics">Metrics</a>
  </li>
  <li>
      <a href="/article/comments/info%3Adoi%2F10.1371%2Fjournal.pone.0000185" name="comments">Comments</a>
  </li>
  <li>
      <a href="/article/related/info%3Adoi%2F10.1371%2Fjournal.pone.0000185" name="related">Related Content</a>
  </li>
  </ul>
</div>

<script type="text/javascript">
  var selected_tab = "article";
</script>
  <div id="figure-thmbs" class="carousel cf">
    <div class="wrapper">
      <div class="slider">
              <div class="item">
                <a href="#pone-0000185-g001" data-doi="info:doi/10.1371/journal.pone.0000185" data-uri="info:doi/10.1371/journal.pone.0000185.g001" title="Figure 1">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000185.g001&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0000185-t001" data-doi="info:doi/10.1371/journal.pone.0000185" data-uri="info:doi/10.1371/journal.pone.0000185.t001" title="Table 1">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000185.t001&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0000185-t002" data-doi="info:doi/10.1371/journal.pone.0000185" data-uri="info:doi/10.1371/journal.pone.0000185.t002" title="Table 2">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000185.t002&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0000185-t003" data-doi="info:doi/10.1371/journal.pone.0000185" data-uri="info:doi/10.1371/journal.pone.0000185.t003" title="Table 3">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000185.t003&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
      </div>
    </div>
  </div>

  <div class="nav-col">
    <div class="nav" id="nav-article-page">
      <ul>
        <li class="nav-col-comments"><a href="/article/comments/info%3Adoi%2F10.1371%2Fjournal.pone.0000185">Reader Comments (0)</a></li>
          <li id="nav-figures"><a data-doi="info:doi/10.1371/journal.pone.0000185" >Figures</a></li>
      </ul>
    </div>
  </div>

  <div class="article">







<div class="abstract"><a id="abstract0" name="abstract0" toc="abstract0" title="Abstract"></a><h2>Abstract</h2>
<h3>Background</h3>
<a id="article1.front1.article-meta1.abstract1.sec1.p1" name="article1.front1.article-meta1.abstract1.sec1.p1"></a><p>In March 2004, the OraQuick® rapid HIV antibody test became the first rapid HIV test approved by the US Food and Drug Administration for use on oral fluid specimens. Test results are available in 20 minutes, and the oral fluid test is non-invasive. From August 2004–June 2005, we investigated a sudden increase in false-positive results occurring in a performance study of OraQuick® oral-fluid rapid HIV tests in Minnesota.</p>


<h3>Methodology/Principal Findings</h3>
<a id="article1.front1.article-meta1.abstract1.sec2.p1" name="article1.front1.article-meta1.abstract1.sec2.p1"></a><p>In a field investigation, we reviewed performance study data on oral-fluid and whole-blood OraQuick® rapid HIV test device lots and expiration dates and assessed test performance and interpretation with oral-fluid and whole-blood specimens by operators who reported false-positive results. We used multivariate logistic regression to evaluate client demographic and risk characteristics associated with false-positive results. Next, we conducted an incidence study of false-positive OraQuick rapid HIV tests in nine US cities and tested both oral-fluid and finger-stick whole-blood specimens from clients; reactive tests were confirmed with Western blot. Sixteen (4.1%) false-positive oral-fluid results occurred in the performance study from April 15, 2004 through August 31, 2004 with unexpired devices from six test lots among 388 HIV-uninfected clients (specificity, 95.9%; 95% CI: 93.4–97.6). Three test operators who had reported false-positive results performed and interpreted the test according to package-insert instructions. In multivariate analysis, only older age was significantly associated with false-positive results (adjusted odds ratio = 4.5, 95% CI: 1.2–25.7). In the incidence study, all valid oral-fluid and whole-blood results from 2,268 clients were concordant and no false-positive results occurred (100% specificity).</p>


<h3>Conclusions/Significance</h3>
<a id="article1.front1.article-meta1.abstract1.sec3.p1" name="article1.front1.article-meta1.abstract1.sec3.p1"></a><p>The field investigation did not identify a cause for the increase in false-positive oral-fluid results, and the incidence study detected no false-positive results. The findings suggest this was an isolated cluster; the test's overall performance was as specified by the manufacturer.</p>

</div>


<div class="articleinfo"><p><strong>Citation: </strong>Jafa K, Patel P, MacKellar DA, Sullivan PS, Delaney KP, et al.  (2007) Investigation of False Positive Results with an Oral Fluid Rapid HIV-1/2 Antibody Test. PLoS ONE 2(1):
          e185.
            doi:10.1371/journal.pone.0000185</p><p><strong>Academic Editor: </strong>Douglas Nixon, University of California, San Francisco, United States of America</p><p><strong>Received:</strong> October 16, 2006; <strong>Accepted:</strong> January 8, 2007; <strong>Published:</strong> January 31, 2007</p><p>This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.</p><p><strong>Funding: </strong>Funding for the investigation described in the manuscript was provided by the Centers for Disease Control and Prevention.</p><p><strong>Competing interests:</strong> The authors have declared that no competing interests exist.</p><p>1</p><p>In this paper we refer to both OraQuick and OraQuick Advance as OraQuick.</p></div>





<div id="section1" class="section"><a id="s1" name="s1" toc="s1" title="Introduction"></a><h3>Introduction</h3><a id="article1.body1.sec1.p1" name="article1.body1.sec1.p1"></a><p>In March 2004, the OraQuick® rapid HIV-1 antibody test (Orasure Technologies, Bethlehem, Pennsylvania, USA) became the first rapid Human Immunodeficiency Virus (HIV) test approved by the US Food and Drug Administration (FDA) for use on oral fluid specimens. In June 2004, the FDA approved the test for HIV-2 antibody detection in oral fluid and a name change to OraQuick® Advance Rapid HIV-1/2 Antibody Test <a href="#pone.0000185-OraSure1">[1]</a>. OraQuick<span class="xref"><sup><a href="#fn2">1</a></sup></span> is a qualitative, visually read lateral-flow immunoassay intended for point-of-care use and is waived for use on oral fluid, finger-stick, and venipuncture whole blood specimens under CLIA (the Clinical Laboratory Improvement Amendments of 1988) <a href="#pone.0000185-Centers1">[2]</a>. The test is performed on an oral fluid specimen, collected by swabbing the flat pad of the test device once around the outer surface of the upper and lower gums, or on 5 µL of whole blood <a href="#pone.0000185-OraSure1">[1]</a>. A reactive test develops reddish-purple lines in both the test and control zones of the device, while a non-reactive test develops a reddish-purple line in the control zone of the device and no line in the test zone <a href="#pone.0000185-OraSure1">[1]</a>. A test is considered invalid if the control or test line develops outside either the control or test zone, if no control line develops, or if a red background in the result window makes it difficult to read the result after 20 minutes <a href="#pone.0000185-OraSure1">[1]</a>. Results are read in 20–40 minutes <a href="#pone.0000185-OraSure1">[1]</a>. Data submitted by the manufacturer as part of an FDA review for approval indicated a specificity of 99.8% (95% confidence interval [CI]: 99.6–99.9) on oral fluid and 100% (95% CI: 99.7–100) on whole blood <a href="#pone.0000185-OraSure1">[1]</a>.</p>
<a id="article1.body1.sec1.p2" name="article1.body1.sec1.p2"></a><p>As part of its Advancing HIV Prevention initiative, the Centers for Disease Control and Prevention (CDC) supports rapid HIV testing methods to increase HIV testing and awareness of HIV status <a href="#pone.0000185-Centers2">[3]</a>. In July 2002, the University of Minnesota's Department of Family Practice initiated a CDC-sponsored study to evaluate the performance of OraQuick to test persons with unknown HIV status in outreach settings <a href="#pone.0000185-Delaney1">[4]</a>. In July 2004, the Minnesota Department of Health requested CDC to investigate a sudden increase in false-positive results with the oral-fluid rapid HIV tests. Test operators described the false-positives as having qualitatively different test lines, but test-line intensity and color were not recorded <a href="#pone.0000185-Delaney1">[4]</a>. In this paper we report on: (1) a field investigation to evaluate false-positive device characteristics, to assess test operator practices, and to retrospectively evaluate performance study client characteristics associated with false-positive test results; and (2) an incidence study of false-positive OraQuick test results to prospectively evaluate client characteristics associated with false-positive test results and device characteristics including test-line intensity and color.</p>
</div>

<div id="section2" class="section"><a id="s2" name="s2" toc="s2" title="Methods"></a><h3>Methods</h3>
<h4>Field Investigation</h4>
<h5>Definitions.</h5><a id="article1.body1.sec2.sec1.sec1.p1" name="article1.body1.sec2.sec1.sec1.p1"></a><p>A false-positive rapid HIV test result was defined as a reactive oral-fluid OraQuick test result followed by a negative FDA-approved serum or oral-fluid Western blot.</p>

<h5>Device investigation.</h5><a id="article1.body1.sec2.sec1.sec2.p1" name="article1.body1.sec2.sec1.sec2.p1"></a><p>We reviewed performance study data for two time periods: July 1, 2002–April 14, 2004 and April 15, 2004–August 31, 2004. The latter corresponded to the time period during which 16 false-positive oral-fluid results were reported. To assess device characteristics associated with false-positive tests, we reviewed test storage conditions at the performance study site and examined expiration dates and manufacturer lot numbers of the tests yielding false-positive results. We requested the manufacturer to report any manufacturing discrepancies for implicated lots.</p>

<h5>Operator investigation.</h5><a id="article1.body1.sec2.sec1.sec3.p1" name="article1.body1.sec2.sec1.sec3.p1"></a><p>We interviewed performance study operators, all of whom had performed and interpreted tests yielding false-positive results, about any unusual device characteristics for those tests. To assess operator practices while performing and interpreting the test we observed operators who reported ≥1 false-positive result as they prepared OraQuick devices, performed one oral-fluid and one finger-stick whole-blood test each on volunteer specimens, inserted devices into the developer solution, timed the test, and interpreted results.</p>

<h5>Epidemiologic investigation.</h5><a id="article1.body1.sec2.sec1.sec4.p1" name="article1.body1.sec2.sec1.sec4.p1"></a><p>We constructed an epidemic curve of false-positive results that occurred during the performance study. To evaluate demographic and risk characteristics potentially associated with false-positive results, we examined client data collected at the time of testing during two time periods: July 1, 2002–April 14, 2004 and April 15, 2004–August 31, 2004. In univariate analyses, we used exact Mantel-Haenszel chi-square tests and exact 95% confidence limits for odds ratios. We included variables associated with false-positive results at <em>P</em>≤0.25 in univariate analysis in a multivariate logistic regression model. We performed all analyses with SAS (version 9.1, SAS Institute, Cary, North Carolina, USA).</p>



<h4>Incidence Study</h4>
<h5>Rationale.</h5><a id="article1.body1.sec2.sec2.sec1.p1" name="article1.body1.sec2.sec2.sec1.p1"></a><p>From February 1, 2005 through May 31, 2005, we conducted a multi-site study of the incidence of false positive results from oral-fluid OraQuick tests because (1) the false-positive results occurred at the end of the Minnesota performance study and it was unknown whether similar incidence would continue; (2) the initial field investigation was retrospective and information on host factors (e.g., pre-existing medical conditions and interfering substances) that might be associated with false-positive results could not be elicited; and, (3) the performance study did not record test line intensity and color, thereby limiting our ability to accurately describe false-positive results read within the 20–40 minute reading window and to determine the degree of under-ascertainment of faintly reactive devices among operators at other sites who had not reported any false positives. If a sufficient number of false-positive results occurred during the incidence study, we planned a case-control study to assess the associations of host factors with false-positive results.</p>

<h5>Definitions.</h5><a id="article1.body1.sec2.sec2.sec2.p1" name="article1.body1.sec2.sec2.sec2.p1"></a><p>For the purpose of the incidence study, we defined a negative HIV test result as one in which the client's whole-blood rapid HIV test result was non-reactive. We defined a positive HIV test result as one with a reactive whole-blood rapid test followed by an FDA-approved positive serum Western blot.</p>

<h5>Sample size.</h5><a id="article1.body1.sec2.sec2.sec3.p1" name="article1.body1.sec2.sec2.sec3.p1"></a><p>We based the sample size calculation for the incidence study on the FDA requirement that, in clinical trials of rapid HIV tests, the lower bound of the 95% confidence interval (CI) for specificity must be at least 98% <a href="#pone.0000185-US1">[5]</a>. With a false-positive incidence of 1.5%, a sample size of 1800 would yield a 95% CI for specificity of 97.9–99.0 <a href="#pone.0000185-Clopper1">[6]</a>. If we observed a false-positive incidence ≥1.5%, the test would not meet FDA specificity requirements and there would be sufficient false-positives for us to proceed with the case-control study.</p>

<h5>Study settings and methods.</h5><a id="article1.body1.sec2.sec2.sec4.p1" name="article1.body1.sec2.sec2.sec4.p1"></a><p>Three state health departments conducted the incidence study from February 1, 2005 through May 31, 2005 at HIV testing sites already using rapid tests in nine cities: Minneapolis, Minnesota; Madison and Milwaukee, Wisconsin; and Atlantic City, East Orange, Hackensack, Newark, New Brunswick and Trenton, New Jersey. Minnesota was invited to participate because the sudden increase in false-positives was reported in Minneapolis; other states volunteered to participate. Clients seeking HIV testing were eligible for enrollment into the incidence study if they were ≥18 years old and had no history of antiretroviral therapy, HIV vaccination, or a previous HIV diagnosis.</p>
<a id="article1.body1.sec2.sec2.sec4.p2" name="article1.body1.sec2.sec2.sec4.p2"></a><p>All incidence study participants consented to and received both whole-blood and oral-fluid OraQuick tests. Participants with concordant non-reactive rapid test results received a negative result, while those with concordant reactive rapid test results received a preliminary positive result. Participants with discordant rapid test results were informed of both results, offered confirmatory testing, and invited to participate in the case-control study. To assess rapid test specificity, any reactive rapid test result was followed by a ‘gold standard’ Genetic Systems HIV-1 Western blot (Bio-Rad Laboratories, Inc., Hercules, California, USA) on serum specimens. Since sensitivity was not under investigation in the incidence study, no additional testing was conducted on concordant non-reactive whole-blood and oral-fluid OraQuick tests (such additional testing was conducted in the performance study and is reported elsewhere <a href="#pone.0000185-Delaney1">[4]</a>). All study operators had received previous training on administration and interpretation of OraQuick. To ensure identification of all false-positive results, we re-trained operators to interpret and record the intensity and color of all test lines observed.</p>

<h5>Data collection and analysis.</h5><a id="article1.body1.sec2.sec2.sec5.p1" name="article1.body1.sec2.sec2.sec5.p1"></a><p>We used QDS™ Questionnaire Development System Version 2.3 (Nova Research Company, Bethesda, Maryland, USA) to record rapid-test results, color and intensity of test and control lines, invalid results, manufacturer lot number, and rapid-test operator initials and read times. Sites also reported Western blot results and routinely collected demographic and risk characteristics of testing clients enrolled as study participants. We calculated specificity with a standard formula and performed all analyses with SAS version 9.1.</p>

<h5>Human subjects.</h5><a id="article1.body1.sec2.sec2.sec6.p1" name="article1.body1.sec2.sec2.sec6.p1"></a><p>As a public-health response to an increase in false-positive test results from an FDA-approved device, CDC determined the study did not require Institutional Review Board (IRB) review under human-subjects-protection guidelines. The Minnesota and Wisconsin IRBs of record concurred. To comply with human-subjects guidelines in New Jersey, the protocol was approved by the New Jersey Department of Health &amp; Senior Services IRB of record.</p>


</div>

<div id="section3" class="section"><a id="s3" name="s3" toc="s3" title="Results"></a><h3>Results</h3>
<h4>Field Investigation</h4>
<h5>Device investigation.</h5><a id="article1.body1.sec3.sec1.sec1.p1" name="article1.body1.sec3.sec1.sec1.p1"></a><p>From July 1, 2002 through April 14, 2004 seven (0.3%) false-positive oral-fluid OraQuick results occurred with test devices from four different lots among 2017 HIV-uninfected clients (<a href="#pone-0000185-g001">Fig. 1</a>). From April 15, 2004 through August 31, 2004, 16 (4.1%) false-positive oral-fluid OraQuick results occurred with test devices from six different lots among 388 HIV-uninfected clients (specificity, 95.9%; 95% CI: 93.4–97.6) (<a href="#pone-0000185-g001">Fig. 1</a>). All false-positive tests were stored and used within the manufacturer's temperature specifications, and used before their expiration date. The manufacturer reported that all implicated lots were manufactured and shipped according to standard procedures and that all device components were within manufacturer specifications.</p>
<div class="figure" id="pone-0000185-g001"><div class="img"><a name="pone-0000185-g001" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000185.g001&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0000185" data-uri="info:doi/10.1371/journal.pone.0000185.g001"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000185.g001&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000185.g001/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000185.g001/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000185.g001/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000185.g001/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0000185.g001.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000185.g001/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000185.g001/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0000185.g001.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 1. </strong></p><a id="article1.body1.sec3.sec1.sec1.fig1.caption1.p1" name="article1.body1.sec3.sec1.sec1.fig1.caption1.p1"></a><p>Epidemic curve of false-positive OraQuick rapid HIV antibody test results, oral fluid, by Month and Lot, University of Minnesota study, July 2002 through August 2004.</p>
<span>doi:10.1371/journal.pone.0000185.g001</span></div>
<h5>Operator investigation.</h5><a id="article1.body1.sec3.sec1.sec2.p1" name="article1.body1.sec3.sec1.sec2.p1"></a><p>Three of the four operators who had observed the 16 false-positive test results were interviewed; one had left the study and could not be contacted. All were involved in the performance study from start to finish and reported that most test lines they observed in devices with false-positive oral-fluid results were faint; some test lines were described as gray. When test lines were faint operators, who worked in teams conducting outreach testing, reported that they occasionally sought the opinion of another operator on whether the test was reactive or non-reactive. Operators did not report any unusual environmental conditions during the period when the increased number of false-positive tests was reported. We observed that all operators used the rapid test on volunteer oral-fluid and whole-blood specimens in accordance with the package insert and interpreted results correctly.</p>

<h5>Epidemiologic investigation.</h5><a id="article1.body1.sec3.sec1.sec3.p1" name="article1.body1.sec3.sec1.sec3.p1"></a><p>No client demographic or risk factors were associated with false positive oral-fluid test results during July 1, 2002–April 14, 2004. Further host-factor analyses were restricted to 382 (94%) clients tested in the performance study during April 15, 2004–August 31, 2004 for whom complete demographic and risk data were available. In univariate analyses age, non-Black race, injection drug use, and male-to-male sex were associated with false-positive results at a threshold of <em>P</em>≤0.25 (<a href="#pone-0000185-t001">Table 1</a>). In the multivariate logistic regression model, only older age was significantly associated (<em>P</em> = 0.02) with false-positive oral-fluid results (<a href="#pone-0000185-t001">Table 1</a>).</p>
<div class="figure" id="pone-0000185-t001"><div class="img"><a name="pone-0000185-t001" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000185.t001&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0000185" data-uri="info:doi/10.1371/journal.pone.0000185.t001"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000185.t001&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000185.t001/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000185.t001/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000185.t001/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000185.t001/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0000185.t001.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000185.t001/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000185.t001/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0000185.t001.TIF"></span>)
                </a></li></ul></div><p><strong>Table 1.  <span>Demographic and risk characteristics of 382 clients who had a true-negative or false-positive oral fluid OraQuick Rapid HIV-1 Antibody Test result—University of Minnesota performance study, April 15, 2004 through August 31, 2004.</span></strong></p><span>doi:10.1371/journal.pone.0000185.t001</span></div>


<h4>Incidence Study</h4>
<h5>Participant characteristics.</h5><a id="article1.body1.sec3.sec2.sec1.p1" name="article1.body1.sec3.sec2.sec1.p1"></a><p>Of 3067 eligible clients at all study sites who received a whole-blood rapid test, 2283 (74%) consented to an oral-fluid rapid test. Of 2283 clients who provided consent, 15 (0.6%) were excluded from analyses because either their test results were read before 20 minutes (n = 9) or their records had missing data (n = 6). Demographic and risk characteristics of the remaining 2268 clients are summarized in <a href="#pone-0000185-t002">Table 2</a>.</p>
<div class="figure" id="pone-0000185-t002"><div class="img"><a name="pone-0000185-t002" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000185.t002&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0000185" data-uri="info:doi/10.1371/journal.pone.0000185.t002"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000185.t002&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000185.t002/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000185.t002/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000185.t002/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000185.t002/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0000185.t002.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000185.t002/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000185.t002/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0000185.t002.TIF"></span>)
                </a></li></ul></div><p><strong>Table 2.  <span>Demographic characteristics and HIV risk behaviors of 2268 clients whose finger-stick whole blood and oral fluid specimens were tested with the OraQuick Advance rapid HIV test, by state—incidence study, February 2005 through May 2005.</span></strong></p><span>doi:10.1371/journal.pone.0000185.t002</span></div>
<h5>Test results.</h5><a id="article1.body1.sec3.sec2.sec2.p1" name="article1.body1.sec3.sec2.sec2.p1"></a><p>Of the 2268 clients tested, results of one (0.04%) test using whole blood and six (0.3%) using oral fluid were invalid. This difference in the number of invalid results by specimen type was not statistically significant (Fisher's exact test, <em>P</em> = 0.12). Nine (0.4%) clients had reactive tests on both oral fluid and whole blood, and 2253 (99.3%) had non-reactive tests on both specimens (<a href="#pone-0000185-t003">Table 3</a>). Valid oral-fluid and whole-blood test results were 100% concordant, and all reactive rapid tests were confirmed as positive by serum Western blot (100% specificity).</p>
<div class="figure" id="pone-0000185-t003"><div class="img"><a name="pone-0000185-t003" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000185.t003&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0000185" data-uri="info:doi/10.1371/journal.pone.0000185.t003"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000185.t003&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000185.t003/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000185.t003/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000185.t003/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000185.t003/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0000185.t003.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000185.t003/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000185.t003/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0000185.t003.TIF"></span>)
                </a></li></ul></div><p><strong>Table 3.  <span>OraQuick Advance rapid HIV antibody test results for 2268 clients tested with oral fluid, Incidence Study, February 2005 to June 2005.</span></strong></p><span>doi:10.1371/journal.pone.0000185.t003</span></div>
<h5>Device characteristics.</h5><a id="article1.body1.sec3.sec2.sec3.p1" name="article1.body1.sec3.sec2.sec3.p1"></a><p>No participant had an invalid test on both whole-blood and oral-fluid specimens. Of the six invalid oral-fluid results, one had a partial reddish-purple test line, three had a red background that did not clear at 20 minutes, and two developed no control lines. All six clients with invalid oral-fluid results had non-reactive whole-blood results and non-reactive repeat oral-fluid results. Two oral fluid tests classified as non-reactive were described by the same reader as having a faint gray test line (<a href="#pone-0000185-t003">Table 3</a>); both clients had non-reactive finger-stick results. The test devices were used on two different days, were read at 20 and 21 minutes respectively, and were from two different lots. The first client whose oral-fluid test device had a gray line was a 62-year old White male who reported multiple sex partners and tested anonymously. The second client was a 47-year old Asian male who reported sex with a known HIV-infected male partner six weeks prior to the current HIV test; he had a negative HIV test result three months prior to the current test. No further HIV test results are available for either client as they did not return to the study site for subsequent testing.</p>


</div>

<div id="section4" class="section"><a id="s4" name="s4" toc="s4" title="Discussion"></a><h3>Discussion</h3><a id="article1.body1.sec4.p1" name="article1.body1.sec4.p1"></a><p>As part of a two year rapid HIV test performance study, a cluster of 16 false-positive oral fluid OraQuick tests was reported from April 15, 2004 through August 31, 2004 during which the specificity of the test fell below the FDA required minimum of 98% <a href="#pone.0000185-Delaney1">[4]</a>, <a href="#pone.0000185-US1">[5]</a>. However, in the first 18 months of the performance study, and in three other contemporaneous studies, oral-fluid OraQuick tests demonstrated a specificity ≥99.6% <a href="#pone.0000185-Delaney1">[4]</a>. The overall specificity of the oral-fluid test for the entire duration of the performance study was 99.0% (95% CI: 98.6–99.4) and there were 23 oral-fluid false positives, 1 oral-fluid false negative, and 2 whole blood false positives <a href="#pone.0000185-Delaney1">[4]</a>. Our field investigation did not suggest a specific cause for the cluster, and our subsequent incidence study detected no false-positive tests. The lack of any false-positive tests despite testing 2268 clients at nine sites during the 4-month incidence study suggests that the observed cluster was isolated and that, even as false-positive results occur at expected rates (we expected two to nine false-positives in the incidence study), future occurrences of false-positive tests may not be evenly distributed over time. While false-positive oral fluid results reported in the performance study occurred in outreach sites, such results have also been reported in a static clinical site (Shelley Facente, personal communication) <a href="#pone.0000185-Wesolowski1">[7]</a>.</p>
<a id="article1.body1.sec4.p2" name="article1.body1.sec4.p2"></a><p>The retrospective nature of the field investigation imposed certain limitations. First, we did not observe test operators performing and interpreting the tests at the time they identified the false-positive results. Although we did not note these practices when the operators performed the tests under our observation, over-collection of oral-fluid specimens (swabbing the outer gums more than once), over-interpretation of the test line, or other practices such as specimen contamination and erroneous recording of results might have contributed to false-positive results. The manufacturer intends to systematically evaluate the influence of oral fluid over-collection on test specificity (Stephen R. Lee, OraSure Technologies, personal communication). Second, we were unable to accurately capture the appearance of the false-positive devices at the time they were identified. We used optical densitometry and detected a peak in the test zone of false-positive devices when compared to a non-reactive device but these readings were obtained days to weeks after the test was run and the devices may have changed appearance in the interim. We were therefore unable to make valid comparisons between interpretations of false-positive devices among operators who had identified them versus operators who had not. Third, we were unable to obtain data retrospectively from persons with false-positive results about medical conditions (e.g., Epstein-Barr virus infection, hepatitis A and B infection, rheumatoid factor, or multiparity) which might be associated with false-positive OraQuick Advance results <a href="#pone.0000185-OraSure1">[1]</a>.</p>
<a id="article1.body1.sec4.p3" name="article1.body1.sec4.p3"></a><p>Older age was significantly associated with false-positive results in the performance study, but age may be a marker for unmeasured conditions that increase with age and that are associated with false-positive results (e.g., prevalence of markers of hepatitis B infection among injection drug users and men who have sex with men). Since no oral-fluid false positives were detected in the incidence study, we were unable to compare age differences between false positives in the performance and incidence study populations. Despite the lack of statistical significance, false-positive results in the performance study occurred more often in specific groups such as injection drug users and men who have sex with men. These findings suggest one or more unmeasured host and site-specific factors may have interacted to produce the cluster. For example, higher rates of viral hepatitis are known to occur in these groups. Both the incidence study and the performance study had similar representation from these groups.</p>
<a id="article1.body1.sec4.p4" name="article1.body1.sec4.p4"></a><p>As with any diagnostic test, comprehensive instructions for performing and interpreting the OraQuick test are essential. The OraQuick Advance package insert does not specify how to interpret partial test lines or visible test lines that do not have a discernable reddish-purple color <a href="#pone.0000185-OraSure1">[1]</a>. In the incidence study, two test lines described by the same operator as very faint or gray were interpreted as non-reactive, and one incomplete reddish-purple test line was considered invalid. All three of these test lines occurred among clients with a negative finger-stick rapid test result; since OraQuick is more sensitive with finger-stick whole blood than with oral fluid it is unlikely these were true positives <a href="#pone.0000185-OraSure1">[1]</a>, <a href="#pone.0000185-Delaney1">[4]</a>. In the original Minnesota performance study and perhaps elsewhere <a href="#pone.0000185-Wesolowski1">[7]</a>, these types of test results may have been reported as reactive. Without guidance from the manufacturer other clusters of false-positive results might occur, in part because of differential interpretation. The manufacturer should revise the package insert to specify how to interpret partial lines and visible lines in the test zone that do not appear reddish-purple.</p>
<a id="article1.body1.sec4.p5" name="article1.body1.sec4.p5"></a><p>With proper training to ensure correct use and interpretation, the OraQuick Advance oral-fluid rapid HIV test can be used successfully as a point-of-care test, although the test has a lower specificity with oral fluid than with whole blood <a href="#pone.0000185-OraSure1">[1]</a>, <a href="#pone.0000185-Delaney1">[4]</a>, <a href="#pone.0000185-Wesolowski1">[7]</a>. Regardless of the specimen type, clients should be counseled that a reactive rapid HIV test result is preliminary and must be confirmed <a href="#pone.0000185-Centers3">[8]</a>, <a href="#pone.0000185-Centers4">[9]</a>.</p>
</div>





<div><a id="ack" name="ack" toc="ack" title="Acknowledgments"></a><h3>Acknowledgments</h3>
<a id="article1.back1.ack1.p1" name="article1.back1.ack1.p1"></a><p>We gratefully acknowledge the following institutions and affiliated staff that contributed to this investigation: Atlantic City Health Department; Bergen County Department of Health; City of Milwaukee Health Department; East Orange Health Department; Henry J. Austin Health Center, Trenton; Madison Department of Public Health; Minnesota Department of Health; New Jersey Department of Health and Senior Services; New York State Department of Health; North Jersey Community Research Initiative; Red Door Clinic, Hennepin County Human Services and Public Health Department; Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey; STD Control Program, Los Angeles County Department of Public Health; and the Wisconsin Division of Public Health.</p>
<a id="article1.back1.ack1.p2" name="article1.back1.ack1.p2"></a><p>The OraQuick Study Group consists of the authors; Stephen J. Swanson and Jeffrey B.Wiener, Centers for Disease Control and Prevention; Amy Doczy, City of Milwaukee Health Department; Deborah Persell, Hennepin County Human Services and Public Health Department; Mary Jo Hussey, Madison Department of Public Health; Peter Carr, Minnesota Department of Health; and Kathleen Krchnavek and James Vergeront, Wisconsin Division of Public Health.</p>
<a id="article1.back1.ack1.p3" name="article1.back1.ack1.p3"></a><p>
            <strong>Disclaimer:</strong> The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or the US Department of Health and Human Services.</p>
</div><div class="contributions"><a id="authcontrib" name="authcontrib" toc="authcontrib" title="Author Contributions"></a><h3>Author Contributions</h3><p>Conceived and designed the experiments: KJ BB PP DM PS KD TS SP EC EM PK SS DP PC KK JV. Performed the experiments: KJ BB PP DM PS KD TS AN EC EM AD DP MH. Analyzed the data: KJ PP DM PS KD JW. Contributed reagents/materials/analysis tools: PK. Wrote the paper: KJ BB PP DM PS KD TS AN SP EC EM PK SS JW AD DP MH PC KK JV. Other: Lead investigator and coordinated all study sites: KJ.</p></div><div><a id="references" name="references" toc="references" title="References"></a><h3>References</h3><ol class="references"><li><span class="label">1.
              </span><a name="pone.0000185-OraSure1" id="pone.0000185-OraSure1"></a>OraSure Technologies Inc. (2004) OraQuick Advance rapid HIV-1/2 antibody test [package insert]. Bethlehem, Pennsylvania: Orasure Technologies.   Available: <a href="http://www.orasure.com/uploaded/398.pdf">http://www.orasure.com/uploaded/398.pdf</a>. Accessed 2007 January 11.  <ul class="find-nolinks"></ul></li><li><span class="label">2.
              </span><a name="pone.0000185-Centers1" id="pone.0000185-Centers1"></a>Centers for Disease Control and Prevention (2006) CLIA certificate of waiver fact sheet.   Available: <a href="http://www.cdc.gov/hiv/rapid_testing/materials/roltCLIA.htm">http://www.cdc.gov/hiv/rapid_testing/mat​erials/roltCLIA.htm</a>. Accessed 2007 January 11.  <ul class="find-nolinks"></ul></li><li><span class="label">3.
              </span><a name="pone.0000185-Centers2" id="pone.0000185-Centers2"></a>Centers for Disease Control and Prevention (2003) Advancing HIV Prevention: new strategies for a changing epidemic—United States, 2003. MMWR Morb Mortal Wkly Rep. 52. (15): pp. 329–332.  Available: <a href="http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5215a1.htm">http://www.cdc.gov/mmwr/preview/mmwrhtml​/mm5215a1.htm</a>. Accessed 2007 January 11.  <ul class="find-nolinks"></ul></li><li><span class="label">4.
              </span><a name="pone.0000185-Delaney1" id="pone.0000185-Delaney1"></a>Delaney KP, Uniyal A, Kerndt PR, Gardener A, Keenan PA, et al.  (2006) Performance of an oral fluid rapid HIV 1/2 test: experience from four CDC studies. AIDS. 20. : 1655–1660.  Available: <a href="http://www.cdc.gov/hiv/topics/testing/rapid/pdf/Delaney_OraQuick_AIDS06.pdf">http://www.cdc.gov/hiv/topics/testing/ra​pid/pdf/Delaney_OraQuick_AIDS06.pdf</a>. Accessed 2007 January 11.  <ul class="find-nolinks"></ul></li><li><span class="label">5.
              </span><a name="pone.0000185-US1" id="pone.0000185-US1"></a>US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (2000) Development of rapid HIV tests. Presented at: Blood Products Advisory Committee Sixty-Sixth Meeting; Volume I; Silver Spring, Maryland.   Available: <a href="http://www.fda.gov/ohrms/dockets/ac/00/transcripts/3620t1.pdf">http://www.fda.gov/ohrms/dockets/ac/00/t​ranscripts/3620t1.pdf</a>. Accessed 2007 January 11.  <ul class="find-nolinks"></ul></li><li><span class="label">6.
              </span><a name="pone.0000185-Clopper1" id="pone.0000185-Clopper1"></a>Clopper C, Pearson E (1934) The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika  26([4]): 404–413.  <ul class="find" data-citedArticleID="928356" data-doi="10.1093/biomet/26.4.404"><li><a href="http://dx.doi.org/10.1093/biomet/26.4.404" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=The+use+of+confidence+or+fiducial+limits+illustrated+in+the+case+of+the+binomial." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22The+use+of+confidence+or+fiducial+limits+illustrated+in+the+case+of+the+binomial.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">7.
              </span><a name="pone.0000185-Wesolowski1" id="pone.0000185-Wesolowski1"></a>Wesolowski LG, MacKellar DA, Facente SN, Dowling T, Ethridge SF, et al.  (2006) Post marketing surveillance of OraQuick® whole blood and oral fluid rapid HIV testing. AIDS. 20. : 1661–1666.  Available: <a href="http://www.cdc.gov/hiv/topics/testing/rapid/pdf/Wesolowski_PMS2_AIDS06.pdf">http://www.cdc.gov/hiv/topics/testing/ra​pid/pdf/Wesolowski_PMS2_AIDS06.pdf</a>. Accessed 2007 January 11.  <ul class="find-nolinks"></ul></li><li><span class="label">8.
              </span><a name="pone.0000185-Centers3" id="pone.0000185-Centers3"></a>Centers for Disease Control and Prevention (2006) HIV counseling with rapid tests.   Available: <a href="http://www.cdc.gov/hiv/pubs/rt-counseling.htm">http://www.cdc.gov/hiv/pubs/rt-counselin​g.htm</a>. Accessed 2007 January 11.  <ul class="find-nolinks"></ul></li><li><span class="label">9.
              </span><a name="pone.0000185-Centers4" id="pone.0000185-Centers4"></a>Centers for Disease Control and Prevention (2004) Notice to readers: Protocols for confirmation of reactive rapid HIV tests. MMWR Morb Mortal Wkly Rep. 53. : 221–2.  Available: <a href="http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5310a7.htm">http://www.cdc.gov/mmwr/preview/mmwrhtml​/mm5310a7.htm</a>. Accessed 2007 January 11.  <ul class="find-nolinks"></ul></li></ol></div>

  </div>

      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.XML" value="94849"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.PDF" value="116704"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.g001.PNG_L" value="21299"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.g001.PNG_M" value="23632"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.g001.PNG_S" value="1816"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.g001.TIF" value="88102"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.g001.PNG_I" value="11010"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.t001.PNG_L" value="238459"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.t001.PNG_M" value="82743"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.t001.PNG_S" value="4735"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.t001.TIF" value="1204104"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.t001.PNG_I" value="35414"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.t002.PNG_L" value="203928"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.t002.PNG_M" value="68855"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.t002.PNG_S" value="3533"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.t002.TIF" value="1046448"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.t002.PNG_I" value="29315"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.t003.PNG_L" value="92406"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.t003.PNG_M" value="31487"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.t003.PNG_S" value="2324"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.t003.TIF" value="526492"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000185.t003.PNG_I" value="13637"/>

</div>
<div class="sidebar">

  <div class="article-actions cf">
      <div class="download">
        <span class="btn"><a href="/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0000185&amp;representation=PDF" title="Download" target="_blank">Download PDF</a></span>
      </div>
      <div class="btn-reveal dropdown">
        <div class="dropdown-icon">
          <span class="btn">&nbsp;</span>
        </div>

        <div class="content">
          <ul class="bullet">
            <li><a href="/article/citationList.action?articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0000185" title="Download citations">Citation</a></li>
            <li><a href="/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0000185&amp;representation=XML" title="Download article XML">XML</a></li>
          </ul>
        </div>
      </div> <!-- end btn-reveal dropdown-->


    <div class="btn-reveal flt-l">
        <span class="btn">Print</span>
        <div class="content">
            <ul class="bullet">
                <li id="print-article"><a href="#" onclick="if(typeof(_gaq) != 'undefined'){ _gaq.push(['_trackEvent','Article', 'Print', 'Click']); } window.print(); return false;" title="Print Article">Print article</a></li>
                <li>
                  <a href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=7&doi=10.1371/journal.pone.0000185&volume=&issue=&title=Investigation of False Positive Results with an Oral Fluid Rapid HIV-1/2 Antibody Test&author_name=Krishna%20Jafa%2C%20Pragna%20Patel%2C%20Duncan%20A.%20MacKellar%2C%20Patrick%20S.%20Sullivan%2C%20Kevin%20P.%20Delaney%2C%20Tracy%20L.%20Sides%2C%20Alexandra%20P.%20Newman%2C%20Sindy%20M.%20Paul%2C%20Evan%20M.%20Cadoff%2C%20Eugene%20G.%20Martin%2C%20Patrick%20A.%20Keenan%2C%20Bernard%20M.%20Branson%2C%20for%20the%20OraQuick%20Study%20Group&start_page=1&end_page=6" title="Odyssey Press">EzReprint</a>
                </li>
            </ul>
        </div>
    </div>

    <div class="btn-reveal flt-r">
        <span class="btn">Share</span>
        <div class="content">
            <ul class="social">
                <li><a href="http://www.reddit.com/submit?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000185" target="_blank" title="Submit to Reddit"><img src="/images/icon.reddit.16.png" width="16" height="16" alt="Reddit">Reddit</a></li>

                <li><a href="https://plus.google.com/share?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000185" target="_blank" title="Share on Google+"><img src="/images/icon.gplus.16.png" width="16" height="16" alt="Google+">Google+</a></li>

                <li><a href="http://www.stumbleupon.com/submit?url=http%3A%2F%2Fwww.plosone.org%2Farticle%2Finfo%253Adoi%252F10.1371%252Fjournal.pone.0000185" target="_blank" title="Add to StumbleUpon"><img src="/images/icon.stumble.16.png" width="16" height="16" alt="StumbleUpon">StumbleUpon</a></li>

                <li><a href="http://www.facebook.com/share.php?u=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000185&amp;t=Investigation%20of%20False%20Positive%20Results%20with%20an%20Oral%20Fluid%20Rapid%20HIV-1%2F2%20Antibody%20Test" target="_blank" title="Share on Facebook"><img src="/images/icon.fb.16.png" width="16" height="16" alt="Facebook">Facebook</a></li>

                <li><a href="http://www.linkedin.com/shareArticle?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000185&title=Investigation%20of%20False%20Positive%20Results%20with%20an%20Oral%20Fluid%20Rapid%20HIV-1%2F2%20Antibody%20Test&summary=Checkout%20this%20article%20I%20found%20at%20PLOS" target="_blank" title="Add to LinkedIn"><img src="/images/icon.linkedin.16.png" width="16" height="16" alt="Mendeley">LinkedIn</a></li>

                <li><a href="http://www.citeulike.org/posturl?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000185&amp;title=Investigation%20of%20False%20Positive%20Results%20with%20an%20Oral%20Fluid%20Rapid%20HIV-1%2F2%20Antibody%20Test" target="_blank" title="Add to CiteULike"><img src="/images/icon.cul.16.png" width="16" height="16" alt="CiteULike">CiteULike</a></li>

                <li><a href="http://www.mendeley.com/import/?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000185" target="_blank" title="Add to Mendeley"><img src="/images/icon.mendeley.16.png" width="16" height="16" alt="Mendeley">Mendeley</a></li>

                <li><a href="https://www.pubchase.com/library?add_aid=10.1371%2Fjournal.pone.0000185&amp;source=plos" target="_blank" title="Add to PubChase"><img src="/images/icon.pc.16.png" width="16" height="16" alt="PubChase">PubChase</a></li>


                <script type="text/javascript">
                    // replace tweet with one that's pre-shortened to 140 chars
                    function truncateTweetText() {
                        var twtTitle = 'Investigation of False Positive Results with an Oral Fluid Rapid HIV-1/2 Antibody Test';
                        var twtUrl = 'http://dx.plos.org/10.1371/journal.pone.0000185';
                        // all URLs posted to twitter get auto-shortened to 20 chars.
                        var maxLength = 140 - (20 + 1);
                        // truncate the title to include space for twtTag and ellipsis (here, 10 = tag length + space + ellipsis)
                        if (twtTitle.length > maxLength) { twtTitle = twtTitle.substr(0, (maxLength - 10)) + '...'; }
                        // set the href to use the shortened tweet
                        $('#twitter-share-link').prop('href', 'http://twitter.com/intent/tweet?text=' + encodeURIComponent('#PLOSONE: ' + twtTitle + ' ' + twtUrl));
                    }
                </script>
                <li><a href="http://twitter.com/intent/tweet?text=#PLOSONE%3A%20Investigation%20of%20False%20Positive%20Results%20with%20an%20Oral%20Fluid%20Rapid%20HIV-1%2F2%20Antibody%20Test http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000185" onclick="truncateTweetText();" target="_blank" title="Share on Twitter" id="twitter-share-link"><img src="/images/icon.twtr.16.png" width="16" height="16" alt="Twitter">Twitter</a></li>

                <li><a href="/article/email/info%3Adoi%2F10.1371%2Fjournal.pone.0000185" title="Email this article"><img src="/images/icon.email.16.png" width="16" height="16" alt="Email">Email</a></li>
            </ul>
        </div>
    </div><!--end btn-reveal flt-r-->
</div><!-- end article-actions-->

<!-- begin Crossmark -->

<a id="open-crossmark" href="#" style="margin-top: -28px; display:block"><img style="border: 0; display: none;
 padding: 10px 0 18px 0;"  id="crossmark-icon" src="/images/logo-crossmark-bw.png" /></a>
<div id="crossmark-dialog" style="display: none;" title="">
    <!-- the external CrossMark data is loaded inside this iframe -->
    <iframe id="crossmark-dialog-frame" frameborder="0"></iframe>
</div>

<!-- end crossmark -->


<div class="block" id="subject-area-sidebar-block">
    <div class="header">
        <h3>Subject Areas</h3><div title="More information" id="subject-area-sidebar-block-help-icon"><img align="right"
                                                                                                           alt="info" src="/images/button_info.png"/><div id="subject-area-sidebar-block-help"><img align="right"
                                                                                                                                                                                                    src="/images/button_info.png"/><p>
        <b>We want your feedback.</b> Do these subject areas make sense for this article? If not, click the flag
        next to the incorrect subject area and we will review it. Thanks for your help!
    </p></div></div>
    </div>


    <ul id="subject-area-sidebar-list">


























          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Blood%22" title="Search for articles in the subject area:'Blood'"><div class="flagText">Blood</div></a>
              <div data-categoryid="31947" data-articleid="23208"
                   data-categoryname="Blood"
                   class="flagImage" title="Flag 'Blood' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Body+fluids%22" title="Search for articles in the subject area:'Body fluids'"><div class="flagText">Body fluids</div></a>
              <div data-categoryid="48757" data-articleid="23208"
                   data-categoryname="Body fluids"
                   class="flagImage" title="Flag 'Body fluids' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22HIV%22" title="Search for articles in the subject area:'HIV'"><div class="flagText">HIV</div></a>
              <div data-categoryid="42663" data-articleid="23208"
                   data-categoryname="HIV"
                   class="flagImage" title="Flag 'HIV' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22HIV+diagnosis+and+management%22" title="Search for articles in the subject area:'HIV diagnosis and management'"><div class="flagText">HIV diagnosis and management</div></a>
              <div data-categoryid="18941" data-articleid="23208"
                   data-categoryname="HIV diagnosis and management"
                   class="flagImage" title="Flag 'HIV diagnosis and management' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22HIV-1%22" title="Search for articles in the subject area:'HIV-1'"><div class="flagText">HIV-1</div></a>
              <div data-categoryid="42863" data-articleid="23208"
                   data-categoryname="HIV-1"
                   class="flagImage" title="Flag 'HIV-1' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Human+performance%22" title="Search for articles in the subject area:'Human performance'"><div class="flagText">Human performance</div></a>
              <div data-categoryid="18145" data-articleid="23208"
                   data-categoryname="Human performance"
                   class="flagImage" title="Flag 'Human performance' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Men+who+have+sex+with+men%22" title="Search for articles in the subject area:'Men who have sex with men'"><div class="flagText">Men who have sex with men</div></a>
              <div data-categoryid="51939" data-articleid="23208"
                   data-categoryname="Men who have sex with men"
                   class="flagImage" title="Flag 'Men who have sex with men' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Population+groupings%22" title="Search for articles in the subject area:'Population groupings'"><div class="flagText">Population groupings</div></a>
              <div data-categoryid="40421" data-articleid="23208"
                   data-categoryname="Population groupings"
                   class="flagImage" title="Flag 'Population groupings' as inappropriate"></div>
          </li>
    </ul>
</div>

<div class="ad">
    <div class="title">Advertisement</div>






  <iframe id='a0852f54' name='a0852f54'
    src='http://ads.plos.org/www/delivery/afr.php?zoneid=381&amp;cb=7019'
    frameborder='0' scrolling='no' width='160' height='600'>
    <a href='http://ads.plos.org/www/delivery/ck.php?n=a0852f54&amp;cb=4347'
      target='_top'><img src='http://ads.plos.org/www/delivery/avw.php?zoneid=381&amp;cb=492&amp;n=a0852f54'
      border='0' alt=''/>
    </a>
  </iframe>



</div>

<div id="twitter-alm-timeline" class="twitter-alm-timeline"></div>


</div><!-- sidebar -->
    </div>
  </div>
</div>
<script src="http://wl.figshare.com/static/p_widget.js" type="text/javascript"></script><div id="pageftr">
  <div class="ftr-cols cf">
    <div class="col col-1">
      <img src="/images/logo-plos-footer.png" alt="PLOS Logo" class="logo" />
      <p><a href="/static/releaseNotes">Ambra 2.9.16</a> Managed Colocation provided <br />by <a href="http://www.isc.org/">Internet Systems Consortium</a>.<p>
      <div class="nav nav-aux">
        <a href="/static/privacy">Privacy Policy</a> |
        <a href="/static/terms">Terms of Use</a> |
        <a href="http://www.plos.org/advertise/">Advertise</a> |
        <a href="http://www.plos.org/about/media-inquiries/">Media Inquiries</a>
      </div>
    </div>
    <div class="col col-2">
      <p><a href="http://www.plos.org/publications/journals/">Publications</a></p>
      <div class="nav">
        <ul>
          <li><a href="http://www.plosbiology.org">PLOS Biology</a></li>
          <li><a href="http://www.plosmedicine.org">PLOS Medicine</a></li>
          <li><a href="http://www.ploscompbiol.org">PLOS Computational Biology</a></li>
          <li><a href="http://currents.plos.org">PLOS Currents</a></li>
          <li><a href="http://www.plosgenetics.org">PLOS Genetics</a></li>
          <li><a href="http://www.plospathogens.org">PLOS Pathogens</a></li>
          <li><a href="http://www.plosone.org">PLOS ONE</a></li>
          <li><a href="http://www.plosntds.org">PLOS Neglected Tropical Diseases</a></li>
        </ul>
      </div>
    </div>
    <div class="col col-3">
      <div class="nav">
        <p><a href="http://www.plos.org">plos.org</a></p>
        <p><a href="http://blogs.plos.org">Blogs</a></p>
        <p><a href="http://www.ploscollections.org">Collections</a></p>
        <p><a href="/feedback/new">Send us feedback</a></p>

        <p>California (US) corporation #C2354500, based in San Francisco</p>
      </div>
    </div>
  </div>
</div><!-- pageftr -->

</div><!-- end page-wrap, this div is in header.ftl -->
<script type="text/javascript" src="/javascript/jquery-1.8.1-min.js?v=Tm7VCOzZz3lE03ghpkS6SWkHbyI"></script>
<script type="text/javascript" src="/javascript/ga-min.js?v=lNQ4gt8QcPDatjsdOFl_FGpPhLY"></script>
<script type="text/javascript" src="/javascript/jquery.hoverIntent-min.js?v=mRiGNYY9cIXxVb8u0K_MdW7hHnc"></script>
<script type="text/javascript" src="/javascript/jquery.placeholder-min.js?v=21Pn56Ur9h1N4K4VZDa0nqI3Pxo"></script>
<script type="text/javascript" src="/javascript/jquery.jsonp-2.4.0-min.js?v=lqTpzoHfSq3I5Ygo01qq5WankEo"></script>
<script type="text/javascript" src="/javascript/jquery-ui-1.9.2.custom-min.js?v=raSSlfNO0YsV5uUpAKmTB9n5VTc"></script>
<script type="text/javascript" src="/javascript/jquery.tooltip-min.js?v=cw+6Smh+mdryIA25xvqIvHMrnZM"></script>
<script type="text/javascript" src="/javascript/jquery.uniform-min.js?v=kYUAnX6W2W_2fK3RIuQ2m_YFG9U"></script>
<script type="text/javascript" src="/javascript/jquery.pjax-min.js?v=939kLBjL5_YKbx71T1RHjYaD4l8"></script>
<script type="text/javascript" src="/javascript/imagesloaded-min.js?v=XeuAp8Gc3mvQUo+wZCSF8ttPwvw"></script>
<script type="text/javascript" src="/javascript/figviewer-min.js?v=yPUa0sUQ_iHkI+IRv2i9bjyZJFo"></script>
<script type="text/javascript" src="/javascript/global-min.js?v=0Q3PwjeaWtXYDnqIsQvnL_ou0qs"></script>
<script type="text/javascript" src="/javascript/jquery.touchswipe-min.js?v=huaek_e6HqTduvCNAN91dJolTyw"></script>
<script type="text/javascript" src="/javascript/jquery.base64-min.js?v=VwV1zeVqKZj5FCAdlK0q5NRxbBg"></script>
<script type="text/javascript" src="/javascript/alm-min.js?v=Y5gm6B0b4Kx2YHNObNrgEeBgXlY"></script>
<script type="text/javascript" src="/javascript/taxonomy-browser-min.js?v=vBVMuDMYkGJCXIUxLe35GoyiJNw"></script>
<script type="text/javascript" src="/javascript/jquery.filterize-min.js?v=j0ZKVnHyk2nhFy8eIuNJkp7xaM0"></script>
<script type="text/javascript" src="/javascript/plosone-min.js?v=TK4H4arL_XBSwwJq+K1N3kqYfAI"></script>
<script type="text/javascript" src="/javascript/twitter-min.js?v=xKgcxLsQFXy+at1ao1NVke8nFlM"></script>
<script type="text/javascript" src="/javascript/crossmark.1.4-min.js?v=3FO4k0SjwTaGNnKGNSqthar1080"></script>
<script type="text/javascript">
  var _sf_async_config={uid:16579,domain:"plosone.org"};
  (function(){
    function loadChartbeat() {
      window._sf_endpt=(new Date()).getTime();
      var e = document.createElement('script');
      e.setAttribute('language', 'javascript');
      e.setAttribute('type', 'text/javascript');
      e.setAttribute('src',
          (("https:" == document.location.protocol) ? "https://a248.e.akamai.net/chartbeat.download.akamai.com/102508/" : "http://static.chartbeat.com/") +
              "js/chartbeat.js");
      document.body.appendChild(e);
    }
    var oldonload = window.onload;
    window.onload = (typeof window.onload != 'function') ?
        loadChartbeat : function() { oldonload(); loadChartbeat(); };
  })();
</script>
<!-- <script type="application/javascript" src="http://crossmark.crossref.org/javascripts/v1.3/crossmark.min.js"></script> -->

</body>
</html>
